Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI 48109, USA.
J Bone Miner Res. 2012 Jan;27(1):11-25. doi: 10.1002/jbmr.508.
Proteoglycan 4 (Prg4), known for its lubricating and protective actions in joints, is a strong candidate regulator of skeletal homeostasis and parathyroid hormone (PTH) anabolism. Prg4 is a PTH-responsive gene in bone and liver. Prg4 null mutant mice were used to investigate the impact of proteoglycan 4 on skeletal development, remodeling, and PTH anabolic actions. Young Prg4 mutant and wild-type mice were administered intermittent PTH(1-34) or vehicle daily from 4 to 21 days. Young Prg4 mutant mice had decreased growth plate hypertrophic zones, trabecular bone, and serum bone formation markers versus wild-type mice, but responded with a similar anabolic response to PTH. Adult Prg4 mutant and wild-type mice were administered intermittent PTH(1-34) or vehicle daily from 16 to 22 weeks. Adult Prg4 mutant mice had decreased trabecular and cortical bone, and blunted PTH-mediated increases in bone mass. Joint range of motion and animal mobility were lower in adult Prg4 mutant versus wild-type mice. Adult Prg4 mutant mice had decreased marrow and liver fibroblast growth factor 2 (FGF-2) mRNA and reduced serum FGF-2, which were normalized by PTH. A single dose of PTH decreased the PTH/PTHrP receptor (PPR), and increased Prg4 and FGF-2 to a similar extent in liver and bone. Proteoglycan 4 supports endochondral bone formation and the attainment of peak trabecular bone mass, and appears to support skeletal homeostasis indirectly by protecting joint function. Bone- and liver-derived FGF-2 likely regulate proteoglycan 4 actions supporting trabeculae formation. Blunted PTH anabolic responses in adult Prg4 mutant mice are associated with altered biomechanical impact secondary to joint failure.
蛋白聚糖 4 (Prg4)因其在关节中的润滑和保护作用而成为骨骼内稳态和甲状旁腺激素 (PTH) 合成代谢的重要调节因子。Prg4 是骨骼和肝脏中 PTH 反应性基因。Prg4 缺失突变体小鼠被用于研究蛋白聚糖 4 对骨骼发育、重塑和 PTH 合成代谢作用的影响。年轻的 Prg4 突变体和野生型小鼠每天接受 4 至 21 天的间歇性 PTH(1-34)或载体治疗。年轻的 Prg4 突变体小鼠的生长板肥大区、小梁骨和血清骨形成标志物均低于野生型小鼠,但对 PTH 的合成代谢反应相似。成年的 Prg4 突变体和野生型小鼠每天接受 16 至 22 周的间歇性 PTH(1-34)或载体治疗。成年的 Prg4 突变体小鼠的小梁骨和皮质骨减少,PTH 介导的骨量增加减弱。与野生型小鼠相比,成年的 Prg4 突变体小鼠的关节活动范围和动物活动能力降低。成年的 Prg4 突变体小鼠的骨髓和肝脏成纤维细胞生长因子 2 (FGF-2)mRNA 减少,血清 FGF-2 减少,PTH 可使这些减少正常化。单次给予 PTH 可降低 PTH/PTHrP 受体 (PPR),并在肝脏和骨骼中使 Prg4 和 FGF-2 增加到相似的程度。蛋白聚糖 4 支持软骨内骨形成和达到小梁骨峰值骨量,并且似乎通过保护关节功能间接支持骨骼内稳态。骨和肝来源的 FGF-2 可能调节支持小梁形成的蛋白聚糖 4 作用。成年的 Prg4 突变体小鼠的 PTH 合成代谢反应减弱与关节功能衰竭导致的生物力学冲击改变有关。